Study of an injectable drug for generalized myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental drug (EA5) injected under the skin or into a vein for people with a specific form of myasthenia gravis (caused by AChR antibodies). The goal is to find the safest dose and see how well it may reduce muscle weakness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years of age or older.
- Your doctor must have confirmed myasthenia gravis with a positive AChR antibody blood test.
- Your body weight must be between 40 and 100 kg (about 88 to 220 pounds).
- Your muscle weakness should be moderate (not just eye symptoms, but not severe enough to need a breathing tube).
- You must be on a stable dose of your current MG medications for at least a few weeks before starting.
- You must have adequate kidney, liver, and blood cell function, and be willing to get vaccinated against certain infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study tests an investigational drug called GC012F for people with generalized myasthenia gravis (gMG) that hasn't improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily life.
This early study tests a new cell therapy (GC012F) for people with difficult-to-treat generalized myasthenia gravis. The treatment aims to reset the immune system to reduce muscle weakness.
This trial tests a new cell therapy called CABA-201 for people with generalized myasthenia gravis. It aims to reset the immune system to reduce muscle weakness and improve daily functioning.
This trial tests a new drug called B007 for people with generalized myasthenia gravis who have specific antibodies and moderate to severe muscle weakness. It aims to see if the drug can improve daily activities and reduce symptoms.
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
Hear when a new Generalized Myasthenia Gravis (gMG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.